North America Medical Enzymes Market 2022-2028
MARKET OUTLOOK
According to Triton Market Research, the North America medical enzymes market is anticipated to develop with a CAGR of 6.57% in the estimated period from 2022 to 2028. The United States and Canada are evaluated in the market in this region.
Cardiovascular disease and cancer are the two leading causes of mortality in Canada, according to a WHO report. A survey by the Canadian Cancer Society had predicted that 118,200 males in Canada would receive cancer diagnoses in 2021, of whom 44,600 were likely to die. As a result, it is anticipated that there would be a strong demand for therapeutic medicinal enzymes used to treat these disorders. This would, in turn, consolidate the medical enzymes market in Canada.
The market in the United States is expected to expand as a result of the market players’ presence in the nation, their partnerships or collaborations, and the introduction of new products by them. For instance, for the treatment of gastrointestinal illnesses, Codexis and Nestle Health Science collaborated on a project for the development of novel enzyme therapies.
Moreover, Codexis also extended its partnership deal with Tate and Lyle, a major provider of food & beverage ingredients, which will aid in the expansion of the company. The company also launched reverse transcriptase to be utilized in one-step reverse transcription, and other similar product launches. Whereas, DuPont introduced Enovera 3001, an enzyme-only solution. Such developments are anticipated to foster market expansion.
COMPETITIVE OUTLOOK
Novus, BBI Solutions, DuPont, Novozymes, Roche Holding AG, Sanofi SA, Thermofisher Scientific Inc, and Brain Biotech AG are some of the noteworthy companies in the medical enzymes market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook